mHealth-Supported Gender- and Culturally Sensitive Weight Loss Intervention for Hispanic Men With Overweight and Obesity: Single-Arm Pilot Study

Background: Hispanic men have disproportionate rates of overweight and obesity compared with other racial and ethnic subpopulations. However, few weight loss interventions have been developed specifically for this high-risk group. Furthermore, the use of mobile health (mHealth) technologies to support lifestyle behavior changes in weight loss interventions for Hispanic men is largely untested. Objective: This single-arm pilot study examined the feasibility and acceptability of integrating mHealth technology into a 12-week gender- and culturally sensitive weight loss intervention (GCSWLI) for Hispanic men with overweight and obesity. Methods: A total of 18 Hispanic men (mean age 38, SD 10.9 years; mean BMI 34.3, SD 5.5 kg/m2; 10/18, 56% Spanish monolingual) received a GCSWLI, including weekly in-person individual sessions, a daily calorie goal, and prescription of ≥225 minutes of moderate-intensity physical activity per week. mHealth technology support included tailored SMS text messaging, behavior self-monitoring support using Fitbit Charge 2, and weight tracking using a Fitbit Aria Wi-Fi Smart Scale. Changes in weight from baseline to 12 weeks were estimated using a paired 2-tailed t test. Descriptive analyses characterized the use of Fitbit and smart scales. Semistructured interviews were conducted immediately after intervention to assess the participants’ weight loss experiences and perspectives on mHealth technologies. Results: Of 18 participants, 16 (89%) completed the 12-week assessments; the overall attrition rate was 11.1%. The mean weight loss at week 12 was −4.7 kg (95% CI 7.1 to −2.4 kg; P<.001). Participants wore the Fitbit 71.58% (962/1344) of the intervention days and logged their body weight using the smart scale (410/1344, 30.51% of the intervention days). Participants identified barriers to the use of the technology, such as lack of technological literacy and unreliable internet access for the smart scale. Conclusions: Although clinically significant weight loss was achieved by integrating mHealth technology into the GCSWLI, adherence to the prescribed use of technology was modest. Addressing barriers to the use of such technologies identified in our work may help to refine an mHealth intervention approach for Hispanic men. ©David O Garcia, Luis A Valdez, Benjamin Aceves, Melanie L Bell, Brooke A Rabe, Edgar A Villavicencio, David G Marrero, Forest Melton, Steven P Hooker.Open access journalThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at [email protected]

Low energy spread 100 MeV-1 GeV electron bunches from laser wakefiel d acceleration at LOASIS

Experiments at the LOASIS laboratory of LBNL recently demonstrated production of 100 MeV electron beams with low energy spread and low divergence from laser wakefield acceleration. The radiation pressure of a 10 TW laser pulse guided over 10 diffraction ranges by a plasma density channel was used to drive an intense plasma wave (wakefield), producing acceleration gradients on the order of 100 GV/m in a mm-scale channel. Beam energy has now been increased from 100 to 1000 MeV by using a cm-scale guiding channel at lower density, driven by a 40 TW laser, demonstrating the anticipated scaling to higher beam energies. Particle simulations indicate that the low energy spread beams were produced from self trapped electrons through the interplay of trapping, loading, and dephasing. Other experiments and simulations are also underway to control injection of particles into the wake, and hence improve beam quality and stability further

Nutrient Applications Reported by Farmers Compared with Performance‐Based Nutrient Management Plans

Bravo-Ureta, B (Bravo-Ureta, Boris)2,3;2. Univ Connecticut, Dep Agr & Resource Econ, Storrs, CT 06269 USA 3. Univ Talca, Dep Agr Econ, Talca, ChileThis study had two main objectives: (i) to evaluate how well farmers implemented nutrient management plans (NMPs) by comparing the farmers' reported practices with the recommended management for manure and fertilizer; and (ii) to evaluate whether the management of manure and fertilizer had significant effects on the nutrient status of soil and corn tissue tests. The analysis relied on data from four dairy farms that had 5 to 7 yr of records at the field level. The farmers chose to apply the recommended amount of fertilizer P from 50 to 100% of the fields. The amount applied was often only 10 to 20 kg P2O5 ha(-1) different from the recommended amount. The farmers applied the recommended amount of fertilizer N from 40 to 71% of the fields when the pre-sidedress soil nitrate test (PSNT) was used for the recommendation, but only 1 to 21% of the fields received the recommended amount when the yield goal method was used. These data suggest that the farmers trusted a fertilizer recommendation developed from a soil test more than they trusted a nonsoil test recommendation. Only a small percentage of fields (3-37%) received the recommended amount of manure N and P. Variability in the amount of residual N available from previous manure applications caused great variation in the PSNT and corn stalk nitrate values (CSNT). This variation in N availability in fields indicates that a number of years of data are needed before the PSNT and the CSNT can be used to objectively evaluate the performance of an NMP

Elezanumab, a human anti-RGMa monoclonal antibody, promotes neuroprotection, neuroplasticity, and neurorecovery following a thoracic hemicompression spinal cord injury in non-human primates.

Spinal cord injury (SCI) is a devastating condition characterized by loss of function, secondary to damaged spinal neurons, disrupted axonal connections, and myelin loss. Spontaneous recovery is limited, and there are no approved pharmaceutical treatments to reduce ongoing damage or promote repair. Repulsive guidance molecule A (RGMa) is upregulated following injury to the central nervous system (CNS), where it is believed to induce neuronal apoptosis and inhibit axonal growth and remyelination. We evaluated elezanumab, a human anti-RGMa monoclonal antibody, in a novel, newly characterized non-human primate (NHP) hemicompression model of thoracic SCI. Systemic intravenous (IV) administration of elezanumab over 6 months was well tolerated and associated with significant improvements in locomotor function. Treatment of animals for 16 weeks with a continuous intrathecal infusion of elezanumab below the lesion was not efficacious. IV elezanumab improved microstructural integrity of extralesional tissue as reflected by higher fractional anisotropy and magnetization transfer ratios in treated vs. untreated animals. IV elezanumab also reduced SCI-induced increases in soluble RGMa in cerebrospinal fluid, and membrane bound RGMa rostral and caudal to the lesion. Anterograde tracing of the corticospinal tract (CST) from the contralesional motor cortex following 20 weeks of IV elezanumab revealed a significant increase in the density of CST fibers emerging from the ipsilesional CST into the medial/ventral gray matter. There was a significant sprouting of serotonergic (5-HT) fibers rostral to the injury and in the ventral horn of lower thoracic regions. These data demonstrate that 6 months of intermittent IV administration of elezanumab, beginning within 24 h after a thoracic SCI, promotes neuroprotection and neuroplasticity of key descending pathways involved in locomotion. These findings emphasize the mechanisms leading to improved recovery of neuromotor functions with elezanumab in acute SCI in NHPs